Fast Five Quiz: Key Aspects of Metastatic Breast Cancer

Elwyn C. Cabebe, MD

Disclosures

December 02, 2021

Treatment with a single endocrine agent or an approved CDK4/6 inhibitor in combination with an endocrine agent is usually continued in patients with metastatic, hormone-responsive breast cancer until disease progression. Considerations are as follows:

  • AIs have been shown to be more effective than tamoxifen for adjuvant therapy and metastatic disease.

  • Postmenopausal women who experience relapse or develop progressive disease on a selective estrogen receptor modulator (eg, tamoxifen) may be switched to an AI.

  • Patients who experience relapse or develop progression of disease while receiving a nonsteroidal AI (eg, anastrozole or letrozole) may be switched to a steroidal AI (eg, exemestane) or a selective estrogen receptor downregulator (eg, fulvestrant).

  • A nonsteroidal AI and a CDK4/6 inhibitor should be offered to postmenopausal patients (and to premenopausal patients combined with chemical ovarian function suppression) with treatment-naive hormone receptor–positive metastatic breast cancer.

  • Fulvestrant and a CDK4/6 inhibitor should be offered to patients with progressive disease during treatment with AIs (or who develop recurrence within 1 year of adjuvant AI therapy) with or without one line of prior chemotherapy for metastatic disease, or as first-line therapy. Treatment should be limited to those without prior exposure to CDK4/6 inhibitors in the metastatic setting.

  • The fulvestrant regimen when administered as monotherapy is 500 mg intramuscularly on days 1, 15, and 29 and once monthly thereafter; it may also be combined with a CDK 4/6 inhibitor, such as abemaciclib, palbociclib, or ribociclib.

  • Optionally, consider the androgenic agent fluoxymesterone (10 mg orally twice daily) or the progestational agent megestrol acetate (40 mg orally four times daily) or estradiol (2 mg orally twice daily).

  • Systemic chemotherapy should be reserved for patients with hormone-insensitive disease or those with symptomatic hormone-sensitive disease who have not responded to any hormone therapy options or who are moderately to severely symptomatic and in urgent need of symptom palliation.

  • The options for cytotoxic-containing chemotherapy include single-agent therapy and combination cytotoxic regimens.

Learn more about endocrine regimens that may be offered as first-line therapy for postmenopausal women with metastatic breast cancer.

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.

processing....